Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill
Weight-loss treatments need to become cheaper and easier to take and lead to less reduction in muscle mass, according to the chief executive of AstraZeneca, which is working with a Chinese company to develop a pill to tackle obesity and type 2 diabetes.
In November, Britain’s biggest drugmaker struck an exclusive licence agreement with Shanghai-based Eccogene, for an experimental drug called ECC5004 that would also treat cardiometabolic conditions such as heart disease and stroke. Obesity and diabetes affect more than 1 billion people globally.
More Stories
Hyundai facing legal action over car that can be stolen ‘effortlessly in seconds’
Canadian company in negotiations with Trump to mine seabed
UK needs to relax AI laws or risk transatlantic ties, thinktank warns